Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere ™ in Routine Care Settings in Greece

Condition:   Pulmonary Disease, Chronic Obstructive (COPD) Intervention:   Combination Product: Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials